DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome

Pathology and Oncology Research

Volumn 19, Issue 2, 2013, Pages 329-343

  Televantou, Despina ^a   Karkavelas, George ^a   Hytiroglou, Prodromos ^a   Lampaki, Sofia ^b   Iliadis, George ^b   Selviaridis, Panagiotis ^a   Polyzoidis, Konstantinos S ^a   Fountzilas, George ^b   Kotoula, Vassiliki ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

DARPP32; Gene expression; Glioblastoma subtyping; IDH negative disease; STAT3; STAT5A; STAT5B; Survivin

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN DARPP 32; PROTEIN KINASE B; PROTEIN PKB; STAT3 PROTEIN; STAT5 PROTEIN; SURVIVIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DOPAMINE AND CAMP REGULATED NEURONAL PHOSPHOPROTEIN 32; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 GENE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 GENE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5 GENE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5A GENE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5B GENE; TUMOR GENE; VALIDATION PROCESS;

APOPTOSIS; BRAIN NEOPLASMS; DACARBAZINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; GLIOBLASTOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 84880702049     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9588-7     Document Type: Article

References (64)

1. WHO (2007) WHO Classification of Tumors of the Central Nervous System. International Agency for Research on Cancer, City
2. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507
3. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120:567-584
4. Yan H, Bigner DD, Velculescu V, Parsons DW (2009) Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 69:9157-9159
5. Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177-183
6. Lai A, Kharbanda S, Pope WB et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482-4490
7. Hartmann C, Hentschel B, Wick W et al (2011) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718
8. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173
9. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
10. Brennan C, Momota H, Hambardzumyan D et al (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4:e7752
11. Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522
12. Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v190-v193
13. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
14. CGARN (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
15. Carro MS, Lim WK, Alvarez MJ et al (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318-325
16. de la Iglesia N, Puram SV, Bonni A (2009) STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med 9:580-590
17. Anderson JC, McFarland BC, Gladson CL (2008) New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med 10:e23
18. Liang QC, Xiong H, Zhao ZW et al (2009) Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Lett 273:164-171
19. Haybaeck J, Obrist P, Schindler CU, Spizzo G, Doppler W (2007) STAT-1 expression in human glioblastoma and peritumoral tissue. Anticancer Res 27:3829-3835
20. Hemmings HC Jr, Greengard P, Tung HY, Cohen P (1984) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310:503-505
21. Brene S, Lindefors N, Ehrlich M et al (1994) Expression of mRNAs encoding ARPP-16/19, ARPP-21, and DARPP-32 in human brain tissue. J Neurosci 14:985-998
22. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P (2004) DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44:269-296
23. Yger M, Girault JA (2011) DARPP-32, Jack of All Trades. Master of Which? Frontiers in behavioral neuroscience 5:56
24. Gu L, Waliany S, Kane SE (2009) Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance. PLoS One 4:e6220
25. Hansen C, Howlin J, Tengholm A et al (2009) Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner. J Biol Chem 284:27533-27543
26. Bogush A, Pedrini S, Pelta-Heller J et al (2007) AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro. J Biol Chem 282:7352-7359
27. Belkhiri A, Dar AA, Zaika A, Kelley M, El-Rifai W (2008) t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 68:395-403
28. Chen F, Xu Y, Luo Y et al (2010) Down-regulation of Stat3 decreases invasion activity and induces apoptosis of human glioma cells. J Mol Neurosci 40:353-359
29. Konnikova L, Kotecki M, Kruger MM, Cochran BH (2003) Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3:23
30. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
31. Zhang F, Wang ZM, Liu HY et al (2011) Application of RT-PCR in formalin-fixed and paraffin-embedded lung cancer tissues. Acta Pharmacol Sinica 31:111-117
32. Sanchez-Navarro I, Gamez-Pozo A, Gonzalez-Baron M et al (2010) Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques 48:389-397
33. Jeuken JW, Cornelissen SJ, Vriezen M et al (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87:1055-1065
34. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL (2006) Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65:1181-1188
35. Spaulding B, Pan D, Ghadersohi A et al (2006) Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues. Histopathology 49:622-633
36. Uematsu M, Ohsawa I, Aokage T et al (2005) Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol 72:231-238
37. Preusser M, Gelpi E, Matej R et al (2005) No prognostic impact of survivin expression in glioblastoma. Acta Neuropathol 109:534-538
38. Johannessen AL, Torp SH (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12:143-147
39. Stupp R, Roila F (2009) Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):126-128
40. Feltus FA, Groner B, Melner MH (1999) Stat5-mediated regulation of the human type II 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene: activation by prolactin. Mol Endocrinol 13:1084-1093
41. Waxman DJ (2000) Growth hormone pulse-activated STAT5 signalling: a unique regulatory mechanism governing sexual dimorphism of liver gene expression. Novartis Found Symp 227:61-74, discussion 75-81
42. Viglietto G, Motti ML, Bruni P et al (2002) Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8:1136-1144
43. Shirai K, Suzuki Y, Oka K et al (2009) Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol 91:353-358
44. Mellai M, Caldera V, Patrucco A, Annovazzi L, Schiffer D (2008) Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis. Anticancer Res 28:109-118
45. Brantley EC, Benveniste EN (2008) Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6:675-684
46. Bhat KP, Salazar KL, Balasubramaniyan V et al (2011) The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 25:2594-2609
47. Cooper LA, Gutman DA, Chisolm C et al (2012) The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 180:2108-2119
48. Kohsaka S, Wang L, Yachi K et al. (2012) STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther
49. Lo HW, Cao X, Zhu H, Ali-Osman F (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14:6042-6054
50. Chumbalkar V, Latha K, Hwang Y et al (2011) Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of DeltaEGFR. J Proteome Res 10:1343-1352
51. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE (2008) Astrocytic regulation of human monocytic/microglial activation. J Immunol 181:5425-5432
52. Tan SH, Nevalainen MT (2008) Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 15:367-390
53. Walker SR, Nelson EA, Zou L et al (2009) Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 7:966-976
54. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL (2008) Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A 105:16707-16712
55. Beckler A, Moskaluk CA, Zaika A et al (2003) Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3′,5′-monophosphate- regulated phosphoprotein in common adenocarcinomas. Cancer 98:1547-1551
56. He F, Sun YE (2007) Glial cells more than support cells? Int J Biochem Cell Biol 39:661-665
57. Visnyei K, Onodera H, Damoiseaux R et al (2011) A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther 10:1818-1828
58. Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17:596-603
59. Fan QW, Weiss WA (2012) Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Methods Mol Biol 821:349-359
60. Koul D, Shen R, Bergh S et al (2006) Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 5:637-644
61. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR (2000) The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 113(Pt 23):4363-4371
62. Espina V, Edmiston KH, Heiby M et al (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7:1998-2018
63. Weller M, Stupp R, Hegi M, Wick W (2012) Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J 18:40-44
64. Marko NF, Quackenbush J, Weil RJ (2011) Why is there a lack of consensus on molecular subgroups of glioblastoma? Understanding the nature of biological and statistical variability in glioblastoma expression data. PLoS One 6:e20826